SCHEMBL24754847

SCHEMBL24754847

CCOC(=O)[C@H](CCc1nc2cc(N(CCCl)CCCl)ccc2n1C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 2/20 0.44
▸ HDAC4 P56524 2/20 0.44
▸ HDAC1 Q13547 2/20 0.44
▸ HDAC2 Q92769 2/20 0.44
▸ HDAC8 Q9BY41 2/20 0.44
▸ HDAC6 Q9UBN7 2/20 0.44
▸ HDAC5 Q9UQL6 2/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ HDAC10 Q969S8 1/20 0.44
▸ REN P00797 3/20 0.39
▸ CTSS P25774 1/20 0.39
▸ CTSK P43235 1/20 0.39
▸ PSMB5 P28074 2/20 0.35
▸ SCN9A Q15858 2/20 0.35
▸ PTPRB P23467 1/20 0.35
▸ PSEN1 P49768 2/20 0.35
▸ PSEN2 P49810 2/20 0.35
▸ APH1B Q8WW43 2/20 0.35
▸ NCSTN Q92542 2/20 0.35
▸ APH1A Q96BI3 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30138549 1.00 HDAC3 (0.44) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL31043293 0.96 HDAC3 (0.47) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL29184777 0.94 HDAC3 (0.47) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL29184784 0.94 HDAC3 (0.47) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL30138478 0.94 HDAC6 (0.47) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL30138516 0.94 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL30138539 0.91 HDAC3 (0.46) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL30138520 0.91 HDAC3 (0.46) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL24755726 0.91 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL24755671 0.91 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240316059-A1 PEPTIDE DRUG CONJUGATES ONCOPEPTIDES AB (SE) 2024-09-26 — — US disclosed
EP-4355370-A1 PEPTIDE DRUG CONJUGATES Oncopeptides Innovation AB (SE) 2024-04-24 — — EP disclosed
WO-2022263679-A1 PEPTIDE DRUG CONJUGATES ONCOPEPTIDES AB (SE) 2022-12-22 — — WO disclosed
WO-2022263679-A1 PEPTIDE DRUG CONJUGATES ONCOPEPTIDES AB (SE) 2022-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316059-A1 PEPTIDE DRUG CONJUGATES MCL1, DNPEP, VIP HDAC3 2573/4885HDAC4 1544/4885HDAC1 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback